-
Something wrong with this record ?
Analgesic effects of piritramide in acute postoperative pain - comparison of intramuscular administration with patient-controlled intravenous analgesia and impact of OPRM1 and ABCB1 polymorphisms
O. Bartosova, M. Sima, O. Polanecky, F. Perlik, S. Adamek, R. Lischke, O. Slanar
Language English Country Czech Republic
Document type Journal Article
NLK
Directory of Open Access Journals
from 2001
Free Medical Journals
from 1998
Medline Complete (EBSCOhost)
from 2007-06-01
ROAD: Directory of Open Access Scholarly Resources
from 2001
PubMed
33252118
DOI
10.5507/bp.2020.053
Knihovny.cz E-resources
- MeSH
- Humans MeSH
- Analgesics, Opioid MeSH
- ATP Binding Cassette Transporter, Subfamily B genetics MeSH
- Analgesia, Patient-Controlled * MeSH
- Pirinitramide * therapeutic use MeSH
- Polymorphism, Genetic MeSH
- Pain, Postoperative drug therapy MeSH
- Receptors, Opioid, mu therapeutic use MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
AIMS: The aim of this study was to compare the efficacy, consumption and safety after piritramide administered either intramuscularly (IM) on demand or via patient-controlled intravenous analgesia (PCA) and to examine the impact of OPRM1 and ABCB1 gene polymorphisms on the drug efficacy/safety in both regimens. METHODS: One hundred and four patients scheduled for elective inguinal hernioplasty received piritramide with PCA or IM for postoperative pain management. We evaluated piritramide consumption, pain intensity using visual analogue scale (VAS) and adverse effects. RESULTS: Median (IQR) piritramide consumption was 18.5 (13.5-31.2) and 15.0 (15.0-15.0) mg in the PCA and IM groups, respectively (P=0.0092). The respective values of area under the VAS2-16-time curve were 40 and 280 mm.h (P=0.0027). Opioid-induced adverse effects were more frequent in the PCA than in the IM group. Variant OPRM1 allele was associated with decreased pain relief, increased opioid consumption and increased incidence of adverse effects, while ABCB1 polymorphisms showed no impact on the observed parameters. CONCLUSIONS: We observed higher piritramide consumption, better pain relief and slightly worse safety profile in the PCA group compared with IM administration. Variant OPRM1 118G allele carriers required higher opioid dosing and suffered from more adverse effects, however, the differences between genotypes have been less pronounced in the PCA patients likely due to improved pain management via PCA.
References provided by Crossref.org
Literatura
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22009431
- 003
- CZ-PrNML
- 005
- 20220815104611.0
- 007
- ta
- 008
- 220419s2022 xr d f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.5507/bp.2020.053 $2 doi
- 035 __
- $a (PubMed)33252118
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xr
- 100 1_
- $a Bartošová, Olga $7 mzk2016928814 $u Department of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Albertov 4, 128 00 Prague 2, Czech Republic
- 245 10
- $a Analgesic effects of piritramide in acute postoperative pain - comparison of intramuscular administration with patient-controlled intravenous analgesia and impact of OPRM1 and ABCB1 polymorphisms / $c O. Bartosova, M. Sima, O. Polanecky, F. Perlik, S. Adamek, R. Lischke, O. Slanar
- 504 __
- $a Literatura
- 520 9_
- $a AIMS: The aim of this study was to compare the efficacy, consumption and safety after piritramide administered either intramuscularly (IM) on demand or via patient-controlled intravenous analgesia (PCA) and to examine the impact of OPRM1 and ABCB1 gene polymorphisms on the drug efficacy/safety in both regimens. METHODS: One hundred and four patients scheduled for elective inguinal hernioplasty received piritramide with PCA or IM for postoperative pain management. We evaluated piritramide consumption, pain intensity using visual analogue scale (VAS) and adverse effects. RESULTS: Median (IQR) piritramide consumption was 18.5 (13.5-31.2) and 15.0 (15.0-15.0) mg in the PCA and IM groups, respectively (P=0.0092). The respective values of area under the VAS2-16-time curve were 40 and 280 mm.h (P=0.0027). Opioid-induced adverse effects were more frequent in the PCA than in the IM group. Variant OPRM1 allele was associated with decreased pain relief, increased opioid consumption and increased incidence of adverse effects, while ABCB1 polymorphisms showed no impact on the observed parameters. CONCLUSIONS: We observed higher piritramide consumption, better pain relief and slightly worse safety profile in the PCA group compared with IM administration. Variant OPRM1 118G allele carriers required higher opioid dosing and suffered from more adverse effects, however, the differences between genotypes have been less pronounced in the PCA patients likely due to improved pain management via PCA.
- 650 _2
- $a P-glykoproteiny $x genetika $7 D018435
- 650 12
- $a pacientem kontrolovaná analgezie $7 D016058
- 650 _2
- $a opioidní analgetika $7 D000701
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a pooperační bolest $x farmakoterapie $7 D010149
- 650 12
- $a pirinitramid $x terapeutické užití $7 D010892
- 650 _2
- $a polymorfismus genetický $7 D011110
- 650 _2
- $a receptory opiátové mu $x terapeutické užití $7 D017450
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Šíma, Martin $7 xx0222901 $u Department of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Albertov 4, 128 00 Prague 2, Czech Republic
- 700 1_
- $a Polanecký, Ondřej $7 xx0086628 $u Third Department of Surgery, First Faculty of Medicine, Charles University in Prague and Motol University Hospital, V Uvalu 84, 150 06 Prague 5, Czech Republic
- 700 1_
- $a Perlík, František, $d 1940-2020 $7 nlk20040147478 $u Department of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Albertov 4, 128 00 Prague 2, Czech Republic
- 700 1_
- $a Adámek, Svatopluk, $d 1950- $7 mzk2007363535 $u Third Department of Surgery, First Faculty of Medicine, Charles University in Prague and Motol University Hospital, V Uvalu 84, 150 06 Prague 5, Czech Republic
- 700 1_
- $a Lischke, Robert, $d 1966- $7 xx0078729 $u Third Department of Surgery, First Faculty of Medicine, Charles University in Prague and Motol University Hospital, V Uvalu 84, 150 06 Prague 5, Czech Republic
- 700 1_
- $a Slanař, Ondřej $7 xx0058262 $u Department of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Albertov 4, 128 00 Prague 2, Czech Republic
- 773 0_
- $w MED00012606 $t Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia $x 1213-8118 $g Roč. 166, č. 1 (2022), s. 40-45
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/33252118 $y Pubmed
- 910 __
- $a ABA008 $b A 1502 $c 958 $y p $z 0
- 990 __
- $a 20220419 $b ABA008
- 991 __
- $a 20220815104609 $b ABA008
- 999 __
- $a ok $b bmc $g 1815562 $s 1160629
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2022 $b 166 $c 1 $d 40-45 $e 20201126 $i 1213-8118 $m Biomedical papers of the Medical Faculty of the University Palacký, Olomouc Czech Republic $n Biomed. Pap. Fac. Med. Palacký Univ. Olomouc Czech Repub. (Print) $x MED00012606
- LZP __
- $b NLK118 $a Pubmed-20220419